MedTrace Logo

Neoadjuvant Herceptin in Patients With Breast Cancer

NCT00133796 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2017-02-07

No results posted yet for this study

Summary

The purposes of this study are to better understand how Herceptin causes tumors to become smaller and to find out how effective Herceptin, together with chemotherapy, is in treating advanced breast cancer.

Conditions

Interventions

DRUG

Herceptin

IV

Sponsors & Collaborators

  • Genentech, Inc.

    collaborator INDUSTRY

  • Mothaffar Rimawi

    lead OTHER

Principal Investigators

  • Mothaffar Rimawi, MD · Baylor Breast Center, Baylor College of Medicine

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-10-31
Primary Completion
2005-09-30
Completion
2007-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00133796 on ClinicalTrials.gov